Efficacy of Sterol Enhanced Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Full Text View

Purpose

It is becoming increasingly clear that North Americans prefer dietary approaches to enhance health in favour of pharmaceutical approaches. Although the consumption of various phytosterol (PS)-enriched foods have been shown to be effective in lowering plasma cholesterol in a variety of food matrices, the lipid-lowering potential of PS-enriched soymilk has not been investigated. Therefore, the objective of this investigation was to examine the lipid-lowering efficacy of a PS-enriched soymilk beverage in comparison to a 1% dairy milk control. Twenty-three hypercholesterolemic subjects (Total-cholesterol and LDL-cholesterol ≥ 5.0 and 3.5 mmol/L, respectively) consumed 3 tetrapacs per day of a phytosterol-enriched soy beverage providing 1.95g PS/d or a 1% dairy milk control. The study was conducted as a 28 d controlled dietary intervention according to a completely randomized, two-period cross-over design.

Condition	Intervention	Phase
Coronary Heart Disease	Dietary Supplement: phytosterol enhanced soy based beverage Dietary Supplement: 1% milk	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Efficacy of Sterol Enhanced Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans Study 1

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol

Drug Information available for: Campesterol

U.S. FDA Resources

Further study details as provided by University of Manitoba:

Primary Outcome Measures:

cholesterol [ Time Frame: 30 days ] [ Designated as safety issue: No ]


Enrollment:	30
Study Start Date:	September 2007
Study Completion Date:	August 2008
Primary Completion Date:	December 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: dairy milk Control phase with 1% milk.	Dietary Supplement: 1% milk
Experimental: phytosterol enhanced soy based beverage Treatment phase where control-phase diets are provided with phytosterol enhanced soy based beverage.	Dietary Supplement: phytosterol enhanced soy based beverage

Eligibility


Ages Eligible for Study:	19 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy males and females, aged 19-60 yr, will be screened for determination of fasting circulating LDL-cholesterol and TG levels.
Subjects accepted into the study will have plasma LDL-C 130-200 mg/dl, TG levels below 250 mg/dl.
The inclusion for body mass index (BMI) range will be 22 to 32 kg/m2.
Subjects must also demonstrate an ability to understand dietary procedures and exercise procedures and be judged as compliant and motivated by the investigators.
Subjects will be permitted to take stable doses of thyroid hormone and anti-hypertensive agents, as long as these are continued equivalently throughout the duration of study.

Exclusion Criteria:

History of recent (i.e. less than 3 months) or chronic use of oral hypolipidemic therapy, including fish oils, or probucol within the last 6 months.
History of chronic use of alcohol (> 2 drinks/day), systemic antibodies, corticosteroids, androgens, or phenytoin.
Myocardial infarction, coronary artery bypass, or other major surgical procedures within the last six months.
Recent onset of angina, congestive heart failure, inflammatory bowel disease, pancreatitis, diabetes, or significant current (ie. onset within past three months) gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of active lesions, chemotherapy or surgery in the past year).
Exercise greater than 15 miles/wk or 4,000 kcal/wk.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00924391

Locations


Canada, Manitoba
Richardson Centre for Functional Foods and Nutraceuticals
Winnipeg, Manitoba, Canada, R3T 2N2

Sponsors and Collaborators

University of Manitoba

WhiteWave Foods, Inc.

Investigators


Principal Investigator:	Peter JH Jones, B.ScM.ScPh.D	Richardson Centre for Functional Foods and Nutraceuticals

More Information

No publications provided by University of Manitoba

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rideout TC, Chan YM, Harding SV, Jones PJ. Low and moderate-fat plant sterol fortified soymilk in modulation of plasma lipids and cholesterol kinetics in subjects with normal to high cholesterol concentrations: report on two randomized crossover studies. Lipids Health Dis. 2009 Oct 20;8:45. doi: 10.1186/1476-511X-8-45.


Responsible Party:	Peter JH Jones, Richardson Centre for Functional Foods and Nutraceuticals
ClinicalTrials.gov Identifier:	NCT00924391 History of Changes
Other Study ID Numbers:	WWB2007:110
Study First Received:	June 16, 2009
Last Updated:	June 17, 2009
Health Authority:	Canada: Ethics Review Committee

Keywords provided by University of Manitoba:


cholesterol plant sterols cholesterol absorption

Additional relevant MeSH terms:


Coronary Artery Disease Coronary Disease Myocardial Ischemia Arterial Occlusive Diseases	Arteriosclerosis Cardiovascular Diseases Heart Diseases Vascular Diseases

ClinicalTrials.gov processed this record on February 27, 2015